THEON wants to spend €300m on HGH, but is the counter-drone prize worth the price?

THEON International Plc (Euronext Amsterdam: THEON) has entered exclusive negotiations to acquire French infrared surveillance specialist HGH Systèmes Infrarouges from Carlyle for an enterprise value of approximately €300 million. The proposed transaction would move THEON deeper into platform electro-optics, multi-domain intelligence, surveillance and reconnaissance, and counter-unmanned aircraft systems. HGH generates approximately €40 million in annual revenue, maintains an EBITDA margin above 40% and has an order backlog of around €70 million. The deal is strategically important because it would accelerate THEON’s transformation from a night vision equipment manufacturer into a broader European defence sensing and situational awareness platform.

Why is THEON willing to pay €300 million for HGH Systèmes Infrarouges?

The valuation reflects the scarcity of profitable European defence technology businesses with proprietary sensors, embedded artificial intelligence and established customer relationships. HGH designs electro-optical and infrared systems capable of automatically detecting, tracking and classifying threats across long distances. These capabilities are increasingly valuable as armed forces confront drones, loitering munitions, low-flying aircraft and other threats that can overwhelm conventional surveillance systems.

HGH also brings financial characteristics that are unusual for a company of its size. Revenue has expanded at an approximately 30% compound annual rate since 2023, while its EBITDA margin exceeds 40%. The €70 million backlog gives the business visibility beyond its current revenue base and reduces the risk that THEON is paying entirely for future expectations.

The headline valuation is still demanding. THEON said the proposed enterprise value represents a mid-to-high teens multiple of HGH’s EBITDA before synergies. Management expects the multiple to fall to around 10 times after full run-rate synergies are achieved in years two to three. That calculation places significant weight on integration, commercial expansion and R&D coordination, meaning the attractive post-synergy multiple will have to be earned rather than simply announced.

How would HGH transform THEON from a night vision supplier into a broader defence platform?

THEON built its reputation through man-portable night vision and thermal imaging systems used by armed and special forces. The company has more than 280,000 systems in service across 72 countries, including 26 NATO members. HGH would add a different layer of capability by extending THEON into fixed, vehicle-mounted, naval and infrastructure-based surveillance.

The strategic shift is important because platform-based systems can carry larger contract values and support longer programme cycles than individual soldier equipment. A supplier that provides both headborne night vision and platform-mounted sensing can address a larger portion of defence procurement budgets. It can also connect information from individual soldiers, vehicles, drones and fixed surveillance assets into a wider operational picture.

THEON has already been moving in this direction. The acquisition of Kappa Optronics added vehicle and aviation electro-optics, while the ShockEOS investment and PHYLAX multi-sensor system expanded the company’s gimbal capabilities. Its partnership with Safran is also aimed at electro-optical systems for unmanned aerial platforms. HGH would accelerate that strategy by adding mature infrared surveillance products rather than requiring THEON to develop every capability internally.

Why are counter-drone systems becoming such an important defence investment category?

Counter-drone technology has moved from a specialist requirement into a core defence priority. Recent conflicts have demonstrated that relatively inexpensive drones can perform surveillance, attack vehicles, disrupt infrastructure and overwhelm traditional air-defence economics. Armed forces therefore need systems that can detect, classify and track small aerial threats before an interceptor or electronic countermeasure can respond.

HGH’s panoramic infrared systems are relevant because detection is the first stage of the counter-drone chain. A countermeasure is not useful if the threat is discovered too late or misclassified. Infrared sensing can complement radar, radio-frequency detection and optical cameras, especially when drones operate with limited electronic emissions or in difficult visibility conditions.

This creates a structural opportunity for THEON. Defence spending is not only increasing in absolute terms, but shifting toward surveillance, battlefield awareness, autonomous systems and layered protection. The proposed HGH acquisition would place THEON closer to these faster-growing budget categories. The opportunity is substantial, although competition from larger defence primes and specialist sensor companies will remain intense.

How does the planned HGH acquisition fit THEON’s broader European consolidation strategy?

THEON is pursuing a deliberate buy-and-build model across European electro-optics. Rather than remaining dependent on one product category, the company has been adding businesses, minority investments and joint ventures that expand technology depth and geographic access. HGH would be one of the largest steps in that strategy.

France is particularly important because it has one of Europe’s most developed defence industrial ecosystems. HGH would provide THEON with a French R&D centre, an export platform and stronger relationships with local suppliers and customers. Keeping HGH’s management team and employees in place should also preserve technical knowledge and reduce the risk that a financially attractive asset loses the engineers who made it attractive.

The wider strategic logic is to build a European electro-optics group capable of competing across multiple domains without becoming dependent on United States-controlled technology. HGH’s systems are described as ITAR-free, which can simplify exports to customers that want fewer restrictions associated with United States defence technology regulations. That independence could become commercially valuable as European governments seek greater sovereignty over critical defence supply chains.

What does THEON’s debt-financed structure mean for shareholders and balance-sheet risk?

THEON plans to finance the proposed acquisition through a bridge facility from BNP Paribas that would later be refinanced entirely with debt. Management does not expect an equity capital increase, which protects existing shareholders from immediate dilution. That is likely one reason the market has reacted constructively to the strategy.

The absence of dilution does not make the transaction financially painless. THEON reported net debt to trailing EBITDA of approximately 1.8 times in its Q1 update, before incorporating the proposed HGH debt. Adding a €300 million acquisition will increase leverage and reduce some of the balance-sheet flexibility available for additional purchases, capacity expansion and shareholder returns.

The key question is how quickly HGH’s cash generation and the expected synergies can reduce leverage. A business with an EBITDA margin above 40% should contribute meaningfully to debt service, particularly if its revenue continues growing. However, execution delays, procurement changes or weaker order conversion could leave THEON carrying more debt for longer than expected.

The funding choice therefore increases both potential returns and financial sensitivity. Debt allows shareholders to retain all the upside if the acquisition succeeds, but it also means they retain the downside if the promised synergies arrive fashionably late.

Can THEON integrate HGH while still delivering its ambitious 2026 growth targets?

THEON entered 2026 with strong operating momentum. First-quarter revenue rose 32.3% to €120.1 million, adjusted EBITDA increased 28.5% to €31.8 million and the adjusted EBIT margin remained at 25%. Management maintained full-year revenue guidance of €570 million to €600 million and a mid-twenties adjusted EBIT margin.

The company also reported a soft backlog of approximately €1.42 billion, including Kappa Optronics, giving it substantial visibility. That backlog reduces near-term demand risk but increases operational pressure. THEON must expand production, secure components, deliver existing contracts and integrate recently acquired businesses while pursuing another major transaction.

HGH is expected to remain under its existing management team, which should reduce immediate disruption. Nevertheless, THEON will need to connect product development, sales channels, procurement and customer relationships without damaging the agility that made HGH successful. Acquisitions often look beautifully compatible before the information technology systems meet.

Integration discipline will be particularly important because THEON is managing several strategic initiatives simultaneously. These include Kappa Optronics, ShockEOS, Harder Digital, the Exosens stake, the Safran partnership and artificial intelligence investments. Each initiative may be attractive individually, but management capacity is not infinitely expandable.

Why could embedded artificial intelligence become the most valuable part of the HGH deal?

HGH has developed proprietary software that uses artificial intelligence and augmented intelligence for long-range threat detection and classification. This capability could become strategically more important than the physical infrared hardware because software determines how effectively sensor data is converted into operational decisions.

Modern defence customers increasingly want systems that reduce the burden on operators. A surveillance platform that constantly produces video without identifying relevant threats creates data rather than intelligence. Artificial intelligence can help filter background activity, identify unusual movement and prioritise targets for human review.

THEON may also be able to combine HGH’s software with sensors from Kappa Optronics, ShockEOS and its existing night vision portfolio. That could support an interconnected ecosystem where information from soldiers, vehicles, drones and fixed surveillance systems is shared across a common operational network.

The risk is that artificial intelligence claims in defence must be validated under difficult real-world conditions. False positives, environmental interference, adversarial countermeasures and software certification can all affect performance. THEON will need to prove that HGH’s algorithms remain reliable across diverse customers, climates and threat environments.

How does THEON’s share price reflect investor confidence and valuation risk?

THEON shares traded around €33.70 on 18 June 2026, gaining approximately 7.5% over five sessions and 11% over one month. The stock remains below its 52-week high of €37 but well above the low of €22.80, giving the company a market capitalisation of approximately €2.6 billion.

The momentum indicates that investors are rewarding THEON’s strong backlog, revenue growth and exposure to rising European defence budgets. The planned HGH acquisition adds another growth catalyst, but it also raises the valuation and execution bar. A stock trading near the upper end of its annual range has less room for integration disappointment.

THEON’s valuation already reflects expectations of sustained double-digit growth and high margins. The acquisition may support those expectations if HGH remains above 40% EBITDA margin and synergies are delivered. If leverage rises while revenue conversion slows, the market could reassess how much acquisition-led growth deserves to be priced upfront.

Analyst sentiment remains constructive, with visible price targets generally above the current share price. The stock’s recent performance suggests the market sees the deal as strategically credible, although much of the easy optimism may already be reflected in the valuation.

What regulatory and execution hurdles remain before the HGH transaction can close?

THEON has entered an exclusivity agreement rather than completing a binding acquisition. The next formal step depends on completing the French employee works council process and executing a definitive share purchase agreement. The transaction will then require customary regulatory approvals.

Foreign investment scrutiny is likely to be relevant because HGH develops sensitive infrared, artificial intelligence and counter-drone technology. French authorities closely monitor changes in ownership involving strategic defence assets. THEON’s European ownership, commitment to maintaining French operations and plan to expand local R&D may support approval, but regulatory timing can still affect completion.

THEON expects the acquisition to close by the fourth quarter of 2026. Until then, investors face the possibility that terms could change, approvals could take longer or negotiations could fail. The industrial logic appears strong, but exclusivity is still one step before marriage.

What happens next if THEON successfully completes the HGH acquisition?

A successful transaction would materially increase the contribution of platform-based intelligence, surveillance and reconnaissance products to THEON’s revenue and profitability. It would also create more opportunities to cross-sell HGH technology through THEON’s global network across Europe, North America, Asia and the Middle East.

The company would need to demonstrate three things quickly. First, HGH’s order backlog must convert into revenue without weakening its margin profile. Second, THEON must show that expected R&D and commercial synergies are tangible rather than spreadsheet decoration. Third, leverage must remain manageable while the wider group continues funding capacity expansion and product development.

If those conditions are met, THEON could emerge as a more diversified European defence electronics company with exposure to soldiers, vehicles, drones, fixed surveillance and counter-UAS applications. Failure would look different. Overpaying, losing key technical employees or allowing debt to constrain investment could turn a strategically attractive acquisition into an expensive distraction.

The proposed deal therefore represents more than another bolt-on. It is a test of whether THEON can convert a successful night vision franchise into a scaled European defence sensing platform without losing the margins, speed and capital discipline that attracted investors in the first place.

Key takeaways on what THEON’s proposed HGH acquisition means for investors and European defence technology

• THEON International Plc has entered exclusive negotiations to acquire HGH Systèmes Infrarouges from Carlyle for an enterprise value of approximately €300 million.
• HGH generates around €40 million of revenue, has an EBITDA margin above 40% and carries an order backlog of approximately €70 million.
• The acquisition would expand THEON beyond man-portable night vision into counter-drone systems, platform electro-optics and multi-domain intelligence, surveillance and reconnaissance.
• HGH’s proprietary infrared sensing and artificial intelligence software would strengthen THEON’s ability to detect and classify threats over long distances.
• THEON expects the transaction to be EBITDA margin accretive and mid-single-digit earnings-per-share accretive in 2027.
• The company plans to finance the deal entirely through debt after using a BNP Paribas bridge facility, avoiding an immediate equity issue but increasing leverage.
• HGH’s French industrial base and ITAR-free technology could strengthen THEON’s position in European defence sovereignty and global export markets.
• THEON must integrate HGH while managing Kappa Optronics, ShockEOS, Harder Digital, Safran initiatives and a rapidly growing €1.42 billion backlog.
• THEON shares are trading near the upper end of their 52-week range, meaning investors are already pricing meaningful growth and execution success.
• The transaction is expected to close by the fourth quarter of 2026, subject to the French works council process, a definitive agreement and regulatory approvals.